🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sault Ste. Marie
Clinical trial register · Canada

Clinical Trials in Sault Ste. Marie, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 2809 Montreal 1902 Vancouver 1179 Calgary 1061 Edmonton 1017
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
National Cancer Institute (NCI)4 AstraZeneca4 Ottawa Hospital Research Institute3 Merck Sharp & Dohme LLC2 Hoffmann-La Roche2
Site location
Toronto2809 Montreal1902 Vancouver1179 Calgary1061 Edmonton1017
All 255 locations
Target enrolment
to

Trials with a site in Sault Ste. Marie

21 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
6.3Fr Versus 7.5Fr Mini-Flexible Ureteroscopy for Renal Stones (MINI-FURS)
NCT07798336Kidney Stones, Nephrolithiasis, Renal Calculi
Sault Area Hospital
Not applicable
308
Sault Ste. Marie
2026-10-01
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
London, Sault Ste. Marie
2026-04-13
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Sacituzumab tirumotecan·Olaparib·Doxorubicin
Merck Sharp & Dohme LLC
Phase 3
2,400
Surrey, Vancouver, St. John's, Barrie, Greater Sudbury, Oshawa, Ottawa, Sault Ste. Marie
2025-06-30
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Surrey, Winnipeg, St. John's, Barrie, London, Sault Ste. Marie, Toronto, Windsor
2025-05-22
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Calgary, Edmonton, Winnipeg, Moncton, Ottawa, Sault Ste. Marie, Toronto, Montreal
2025-04-09
Recruiting
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
NCT06603870Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
DrugApixaban
Ottawa Hospital Research Institute
Phase 4
330
Ottawa, Sault Ste. Marie
2024-12-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin
AstraZeneca
Phase 3
1,160
Abbotsford British Columbia, Saint John, Sydney, Greater Sudbury, Hamilton, Kingston, Sault Ste. Marie, Montreal
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Saint John, Sydney, Greater Sudbury, Hamilton, Sault Ste. Marie, Montreal
2024-11-18
Active, closed
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
NCT06440967Hot Flashes
DrugsFezolinetant·Tamoxifen
Astellas Pharma Global Development, Inc.
Phase 3
982
Sarnia, Sault Ste. Marie, Montreal, Québec, Sherbrooke, Victoriaville, Trois-Rivières
2024-07-31
Recruiting
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
NCT05417516Breast Neoplasm Female, Radiotherapy, Cosmetic Outcome
Ontario Clinical Oncology Group (OCOG)
Phase 3
910
Calgary, Victoria, Halifax, Barrie, Hamilton, London, Newmarket, Sault Ste. Marie
2023-11-20
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Calgary, Kelowna, Winnipeg, Barrie, Ottawa, Sault Ste. Marie, Toronto, Windsor
2023-03-31
Recruiting
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
NCT05029063Venous Thromboembolism, Cancer
DrugRivaroxaban
Ottawa Hospital Research Institute
Phase 3
1,828
Halifax, Brampton, Hamilton, Ottawa, Sault Ste. Marie, St. Catharines, Windsor, Greenfield Park
2022-10-05
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Calgary, Edmonton, Vancouver, Moncton, Sault Ste. Marie, Chicoutimi, Greenfield Park, Montreal
2021-08-27
Active, closed
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04093167Lung Cancer
DrugPembrolizumab
Canadian Cancer Trials Group
Phase 2/3
53
Edmonton, Vancouver, Greater Sudbury, Hamilton, Kingston, Ottawa, Sault Ste. Marie, Toronto
2020-05-26
Active, closed
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
DrugsKeytruda·Paclitaxel·Carboplatin·Pembrolizumab
National Cancer Institute (NCI)
Phase 3
813
Moncton, Barrie, Greater Sudbury, Hamilton, Kingston, London, Oshawa, Sault Ste. Marie
2019-08-22
Active, closed
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796Neoplasms
DrugsNiraparib·Dostarlimab·Paclitaxel·Carboplatin
Tesaro, Inc.
Phase 3
785
Calgary, Winnipeg, Ottawa, Sault Ste. Marie, Toronto, Montreal, Québec
2019-07-18
Active, closed
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
DrugNivolumab
National Cancer Institute (NCI)
Phase 3
344
Calgary, Vancouver, St. John's, London, Ottawa, Sault Ste. Marie, Toronto, Regina
2018-07-05
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsPegylated Liposomal Doxorubicin Hydrochloride·Cediranib Maleate·Liposomal doxorubicin·Topotecan
National Cancer Institute (NCI)
Phase 2/3
582
Calgary, Edmonton, Barrie, Hamilton, Kingston, London, Sault Ste. Marie, Toronto
2016-05-03
Active, closed
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
DrugsPegylated Liposomal Doxorubicin Hydrochloride·Cediranib Maleate·Liposomal doxorubicin·Olaparib
National Cancer Institute (NCI)
Phase 3
579
Calgary, Edmonton, Hamilton, London, Ottawa, Sault Ste. Marie, Toronto, Montreal
2016-03-28
Active, closed
Pilot Study of The EPIC Trial
NCT02533206Sinusitis, Nasal Polyps
Ottawa Hospital Research Institute
Not applicable
20
Barrie, London, Ottawa, Sault Ste. Marie, Toronto
2015-08
Active, closed
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282Non-Small-Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
1,118
Greater Sudbury, Kingston, Newmarket, Oshawa, Saint Catherines, Sault Ste. Marie, Toronto, Regina
2015-07-21
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-canada/city/sault-ste-marie

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Sault Ste. Marie.

How many clinical trials are recruiting in Sault Ste. Marie?

10 of the 21 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sault Ste. Marie), 21 studies
PhaseStudiesRecruitingShare
Phase 316976.2%
Not applicable209.5%
Phase 2/3209.5%
Phase 4114.8%

Most active sponsors

Lead sponsors with the most studies (Sault Ste. Marie)
Lead sponsorStudiesRecruiting
AstraZeneca43
National Cancer Institute (NCI)40
Ottawa Hospital Research Institute32
Hoffmann-La Roche21
Merck Sharp & Dohme LLC22
Astellas Pharma Global Development, Inc.10
Boehringer Ingelheim11
Canadian Cancer Trials Group10
Ontario Clinical Oncology Group (OCOG)11
Sault Area Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.